HOPA Member Award Winners

Nearly 20 Years of Member Recognition

Please note, many of our Member Awards have been created throughout our nearly 20-year history. As a result, some lists date back farther than others. In addition, you may notice that names and titles reflect information we had on file at the time of the award and may not be current.

Congratulations to the 2024 HOPA Award Winners

Diversity, Equity and Inclusion Award Onyebuchi Ononogbu PharmD, BCOP
Pharmacy Technician Award Heather Cranford CPhT
Leadership Award Julie Kennerly-Shah PharmD, MS, MHA, BCP
Mentorship Award Rebecca Fahrenbruch PharmD, BCOP, FHOPA
New Practitioner Award Benjamin Andrick PharmD, BCOP
Outstanding Clinician Award Kayleigh R Marx PharmD, BCOP
Patient Advocacy Award Stephen J Lirette PharmD, BCOP
Volunteer Award Shawn Patrick Griffin PharmD, BCOP
Basic Science and Clinical Research Literature Award Alexandre Chan PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APh
Oncology Pharmacy Literature Award Melissa Carroll PharmD, BCPS
Spacer Image

Previous Member Award Winners

2023 - Casey B. Williams, PharmD MBA BCOP FHOPA

2020-22 - Not Awarded

2019 - George Carro, RPh MS BCOP

2018 - R. Donald Harvey, PharmD BCOP FCCP FHOPA

2017 - Terri G. Davidson, PharmD BCCP BCOP FASHP

2016 - Niesha L. Griffith, MS RPh FASHP

2015 - David W. Henry, MS BCOP FASHP

2014 - Rowena N. Schwartz, PharmD BCOP

2013 - Robert Ignoffo, PharmD FASHP FCSHP

2012 - Susan Goodin, PharmD

2011 - Jim Koeller, MS

2010 - Val R. Adams, PharmD FCCP BCOP

2009 - Barry R. Goldspiel, PharmD BCOP BCPS FASHP FISOPP

2008 - Carol M. Balmer, PharmD BCOP

2007 - Jane M. Pruemer, PharmD BCOP FASHP

2006 - Judy L. Chase, PharmD FASHP

2006 - Amy W. Valley, PharmD BCOP

2005 - LeAnne D. Kennedy, BCOP

2023 - Zanette Kanani Bradley, PharmD BCOP

2023 - Mya Merrow, PharmD BCOP

2022 - Maurice Alexander, PharmD, BCOP

2022 - Britny R. Brown, PharmD, BCOP

2023 - Sarah Cimino, PharmD BCOP

2023 - C. Brooke Adams, PharmD BCOP

2022 - Kathryn Maples, PharmD BCOP

2021 - Justin Arnall, PharmD BCOP

2020 - Kirollos S. Hanna, PharmD BCPS BCOP

2020 - Megan N. Dillaman, PharmD BCOP

2019 - Megan May, PharmD BCOP

2018 - Alexandra Shillingburg, PharmD BCOP

2017 - Amber Bradley Clemmons, PharmD BCOP

2016 - Kristin Held Wheatley, PharmD BCOP

2015 - Patrick J. Kiel, PharmD BCPS BCOP

2014 - Robert S. Mancini, PharmD BCOP

2013 - Steve Stricker, PharmD MS BCOP

2012 - Daniel Zlott, PharmD BCOP

2011 - Trevor McKibbin, PharmD MS BCPS

2010 - LeAnn Best Norris, PharmD BCPS BCOP

2009 - Julianna Burzynski, PharmD BCPS BCOP

2008 - Janet Espirito, PharmD BCOP

2023 - Allison Kane, PharmD

2022 - Sarah E. Wheeler, PharmD BCOP

2021 - Megan Langer, PharmD BCOP

2020 - Kathy Hogan Edwards, PharmD BCPS BCOP

2019 - Ashley Glode, PharmD BCOP

2018 - Not Awarded

2017 - Kerry Parsons, PharmD BCOP FHOPA

2016 - Benyam Muluneh, PharmD BCOP CPP

2015 - Rowena N. Schwartz, PharmD BCOP

2014 - Sarah S. Hudson-DiSalle, PharmD RPh

2023 - Tabitha Sowers Alvarado, AA CPhT

2022 - Alicia M. Holguin, CPhT

2022- May Lo, PharmD RPh

2021 - Emily Zimdars, BA, CPhT

2021 - Jessica Turner, CPhT

2020 - Alexamil Rodriguez, CPhT

2019 - Amanda Pate, CPhT

2018- Desiree Rolniak, CPhT

2017 - Cheryl Hyk, MA CPhT

2016 - Edward D. Gormley, BS CPhT

2012-2015 - Not Awarded

2011 - Tanja Monroe

2010 - Therese McGrain, CPhT

2009 - Jeanne Anderson, CPhT

2008 - Kenneth Grohgans, CPhT

2007 - Darrell Clarke, CPhT

2007 - Anne Hameed, CPhT

2023 - C. Brooke Adams, PharmD BCOP

2022 - Mallika P. Patel, PharmD, CPP

2020 - Eve-Michell Segal, PharmD, BCOP

2021 - Not Awarded

2019 - Ila Saunders, PharmD BCOP

2023 - Robert S. Mancini, PharmD, BCOP, FHOPA

2022 - Not Awarded

2021 - Ali McBride, PharmD, MS

2023 - Jonathan Cohen, PharmD, BCOP, Lee C, Markham R, Szerwo J, Roska M, Bubalo J. Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: Guidance for clinical and oncology pharmacists. J Am Coll Clin Pharm. 2022;1-53. DOI: 10.1002/jac5.1698

2022 - Shannon Hough, PharmD, BCOP, Hough S, McDevitt R, Nachar VR, Kraft S, Brown A, Christen C, Frame D, Smerage JB. Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting. JCO Oncol Pract. 2021 Feb 3:OP2000639. doi: 10.1200/OP.20.00639

2021 - Grant Lee, PharmD, Lee GW, Mathur AD, Andrick BJ, Leese E, Zally D, Gatson NTN. Pharmacist value-added to neuro-oncology subspecialty clinics: a pilot study uncovers opportunities for best practices and optimal time utilization. J Oncol Pharm Pract. 2020 Sep 17;1078155220957738. PubMed PMID: 32938297.

2020 - Jacqueline L. Olin, M.S., PharmD, BCPS, Olin JL, Klibanov O, Chan A, Spooner LM. Managing pharmacotherapy in people living with HIV and concomitant malignancy. Ann Pharmacother 2019 Aug;53(8):812-832. doi: 10.1177/1060028019833038. Epub 2019 Feb 15.

2019 - Julianne Orr, PharmD BCOP, Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, Deremer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation. 2018;24(10):2065–71.

2018 - NA

2017 - Karen Sweiss, PharmD, Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 2016; e-pub ahead of print 16 May 2016; doi:10.1038/bmt.2016.136.

2016 - Ginah Nightingale, PharmD BCOP, Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33:1453-1459.

2015 - Joseph S. Bubalo, PharmD BCOP BCPS, Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi:10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23.

2014 - Ali McBride, PharmD MS BCPS BCOP, McBride A, Lathon S, Boehmer L, Augustin KM, Butler SK, Westervelt P. Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome. Pharmacotherapy. 2013;33(3):295-303.

2013 - Kamakshi V. Rao, PharmD BCOP CPP, Strother RM, Rao KV, Gregory KM, Jakait B, Busakhala N, Schellhase E, Pastakia S, Krzyzanowski M, Loehrer PJ. The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya. J Oncol Pharm Pract 2012. Jan 16

2012 - Kristine R. Crews, PharmD, BCPS, Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011

2011 - NA

2010 - Brian Crandell, PharmD, BCOP, O'Bryant CL, Crandell BC. Community pharmacists’ knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008;48:632-9.

2023 - Aaron W. Stewart, PharmD, CTTS, Shillingburg A, Petros W, Wen S, Piktel D, Moses R, Gibson LF, Craig M, Cumpston A. A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non-obese controls. Pharmacotherapy. 2022 Jan;42(1):53-57. doi: 10.1002/phar.2646. Epub 2021 Nov 22. PMID: 34767652.

2022 - Lydia Benitez, PharmD, BCOP Benitez, LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin S, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378. Epub ahead of print. PMID: 33830856.

2021 - Victoria Nachar, PharmD, BCOP, Hoylman E, Brown A, Perissinotti A, et al. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2020 Mar;61(3):691-698

2020 -Daniel J. Crona, PharmD, PhD, CPP, Crona DJ, Skol AD, Leppänen V-M, Glubb DM, Etheridge AS, Hilliard E, Peña C, Peterson Y, Klauber-DeMore N, Alitalo KK, Innocenti F. Novel genetic determinants of survival in renal cell carcinoma patients treated with sorafenib: a clinical and translational experimental study. Cancer Res. 2019 Jan; 79(1):231-241. PMCID: PMC6541205.

2019 - Judith A. Smith, BS PharmD BCOP CPHQ FCCP FISOPP, Cotton S, Brown RE, Nugent EK, Robazetti SC, Berens PD, Smith JA. Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections. Obstetrics & Gynecology. 2018Apr;131(4):681–7.

2018 - NA

2017 - NA

2016 - Meghana V. Trivedi, PharmD PhD BCOP, Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2015 Oct;153(3):591-7. Epub 2015 Sep 4.

2015 - David J. Reeves, PharmD BCOP, Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014 Sep;78(3):565-71. Doi: 10.1111/bcp.12384 PMID: 24646036

2014 -Casey B. Williams, PharmD BCOP, Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia. Pharmacotherapy. 2013 Jun 24. doi: 10.1002/phar.1316.

2013 - Wendelin Nelson, PharmD BCOP, Nelson WK, Formica RN, Cooper DL, Schwartz PE, Rutherford TJ. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. J Oncol Pharm Pract 2012;18(3):323-332.

2012 - Cindy O'Bryant, PharmD BCOP FCCP, O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 2011 Sep 22

2011 - Jacob K. Kettle, PharmD, Kettle JK, Grauer D, Folker TL, et al. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy. Pharmacotherapy. 2010;30(8):812-817.

2010 - LeAnne Kennedy, PharmD, BCOP, Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion. 2008;48:2285-91.

2009 - Stacy S. Shord, PharmD, BCOP, Sandra Cuellar, PharmD, BCOP, Shord SS, Hamilton JM Jr, Cuellar S. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia. J Oncol Pharm Pract. 2008;14:5-22.

2007 - Donald A. Hutcherson, RPh Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006;26:242-247.

2006 - Susan Goodin, PharmD, BCOP, Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55:117-142

2007 - Dominic A. Solimando Jr, MA, RPh, BCOP, FAPhA, FASHP

2006 - David Baribeault, RPh, BCOP and Sachin Shah, PharmD, BCOP